These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31617673)

  • 1. Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
    Guerra-García P; Marshall LV; Cockle JV; Ramachandran PV; Saran FH; Jones C; Carceller F
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28011. PubMed ID: 31617673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
    J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
    Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
    Wang Q; He Z; Chen Y
    Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
    Rinne ML; Wen PY
    Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
    [No Abstract]   [Full Text] [Related]  

  • 10. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
    Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
    J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
    Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
    Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
    Li ZY; Yuan SW; Song YY; Hameed NUF; Chen H; Zhuang DX; Lu JF; Gong FY; Aibaidula A; Shi ZF; Wu S; Guo QH; Wu JS
    Chin Med J (Engl); 2021 Mar; 134(11):1356-1358. PubMed ID: 33788781
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamic history of low-grade gliomas before and after temozolomide treatment.
    Ricard D; Kaloshi G; Amiel-Benouaich A; Lejeune J; Marie Y; Mandonnet E; Kujas M; Mokhtari K; Taillibert S; Laigle-Donadey F; Carpentier AF; Omuro A; Capelle L; Duffau H; Cornu P; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
    De Vos FY; Gijtenbeek JM; Bleeker-Rovers CP; van Herpen CM
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):373-82. PubMed ID: 22925496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
    van den Bent MJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 19):39-44. PubMed ID: 14765384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of temozolomide in recurrent malignant gliomas.
    Gaya A; Rees J; Greenstein A; Stebbing J
    Cancer Treat Rev; 2002 Apr; 28(2):115-20. PubMed ID: 12297119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

  • 18. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
    Liang ML; Hsieh TH; Ng KH; Tsai YN; Tsai CF; Chao ME; Liu DJ; Chu SS; Chen W; Liu YR; Liu RS; Lin SC; Ho DM; Wong TT; Yang MH; Wang HW
    Oncotarget; 2016 Apr; 7(15):19723-37. PubMed ID: 26933822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
    Tan Z; Zhao J; Jiang Y
    Cancer Med; 2018 Mar; 7(3):913-921. PubMed ID: 29473317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.